Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting

The standard of care for patients with relapsed or refractory classic Hodgkin lymphoma (HL) after front-line treatment is salvage chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) [1,2]. Several strategies have been explored to prevent relapse after auto-HSCT, including involved-field radiation, immunotherapy, tandem auto-HSCT, and allogeneic HSCT [3-5]. Given the short- and long-term side effects of previous chemotherapies and high-dose conditioning regimens during HSCT, post-transplant therapies should have manageable safety profiles that do not compromise their efficacy or patients' quality of life [6].

Source: Biology of Blood and Marrow Transplantation - May 30, 2018 Category: Hematology Authors: Auayporn Nademanee, Anna Sureda, Patrick Stiff, Jerzy Holowiecki, Muneer Abidi, Naomi Hunder Hunder, Michael Pecsok, Mayur Uttarwar, Indra Purevjal, John Sweetenham Source Type: research